Advertisement

Topics

Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia

07:30 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi®) compared to anagrelide for the treatment of patients with essential thrombocyt...

Other Sources for this Article

Media
Catalina Loveman, +1-302-498-6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1-302-498-5914
mbooth@incyte.com

NEXT ARTICLE

More From BioPortfolio on "Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...